Chief Financial Officer Tom Adams attributed U.S. growth to “higher consumable volumes from new patient starts and market share gains within new and existing accounts against a healthy SCIg market backdrop.” International growth was driven by “higher pumps and consumable volumes in support of pre-filled syringe conversions in the EU market,” with Adams noting strong first-quarter distributor orders in a new 50 mL prefill market and an expectation that “end user pull-through of our consumables” would follow. ...